Biotronik’s Pulsar stents show efficacy in new studies

Biotronik has shared new study data at the Cardiovascular and Interventional Radiological Society of Europe congress which underlines the benefits of its Pulsar-18 self-expanding stent system.

At the industry event in Barcelona, the company shared 24-month results from the prospective multi-centre 4EVER study, which investigated both the acute and long-term performance of four F-compatible devices in superficial femoral artery lesions.

It was found that the efficacy of Biotronik's device compared very favourably with other bare-metal stent trialled in similar clinical conditions, offering a 72.3 percent primary patency rate and a freedom from target lesion revascularisation rate of 82.7 percent.

These findings were backed up by 12-month data from the Peace registry, in which the stents showed a similarly strong performance.

Dr Alexander Uhl, vice-president for marketing at Biotronik's vascular interventions division, said: "We are very pleased that Pulsar-18 has shown such favourable results in comparison to other stents on the market."

This comes after the company showcased a number of its latest innovations at the recent Heart Rhythm Congress, which took place in Birmingham last month.